{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'Table 3.', 'Schedule of Assessments: Part 2 of Study BCX7353-302', 'Part 2', 'Assessment', 'Double-Blind, Active Study Drug Administration', 'Week 26b', 'Week 28', 'Week 32', 'Week 36', 'Week 40', 'Week 44', 'Week 48', 'Day 183', 'Day 197', 'Day 225', 'Day 253', 'Day 337', '2 days', '2 days', '2 days', '2 days', '+ 7 days', 'In-clinic evaluations', 'X', 'X', 'X', 'X', 'X', 'Telephone contact', 'X', 'X', 'Subject weight', 'X', 'X', 'X', 'X\u00b0', 'Physical examinationd', 'X', 'X', 'X', 'X', 'Urine pregnancy testP', 'X', 'X', 'X', 'X', 'Vital signse', 'X', 'X', 'X', 'X', 'Safety laboratory evaluations', 'Xb', 'X', 'X', 'X', 'X', 'Troponin I and Troponin T', 'X', 'X', 'X', 'X', 'NGAL', 'X', 'X', 'X', 'X', 'CK-MB', 'X', 'X', 'X', 'X', 'Urinalysist', 'Xb', 'X', 'X', 'X', 'X', '12-lead ECGR', 'X', 'X', 'X', 'X', 'EQ-5D-5Lh,', 'X', 'X', 'X', 'X', 'AE-QoL, TSQM, WPAI', 'X', 'X', 'X', 'X', 'Concomitant medications', 'AEs', 'e-diary instruction/review', 'X', 'X', 'X', 'X', 'X', 'X', 'e-diary daily completion', 'Study drug dosing\u00b9', 'Investigator confirmation of attacks\"', 'Study drug accountability/ dispensing', 'X', 'X', 'X', 'X', 'Plasma for PK analysis\u00b0', 'X', 'X', 'X', 'X', 'Plasma for kallikrein inhibition\u00b0', 'X', 'X', 'X', 'X', 'Abbreviations: AE = adverse event; AE-QoL = Angioedema Quality of Life; ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate', 'aminotransferase; EQ-5D-5L = EuroQoL 5-dimensional, 5-level questionnaire; CK-MB = creatine kinase MB isoenzyme; CRF = case report form;', 'ECG = electrocardiogram; e-diary = electronic diary; GGT = gamma glutamyl transferase; HAE = hereditary angioedema ; NGAL = neutrophil', \"gelatinase-associated lipocalin; PD = pharmacodynamic; PK = pharmacokinetic; QoL = quality of life; QTcF = QT interval corrected using Fridericia's method;\", 'TSQM = Treatment Satisfaction Questionnaire for Medication; WPAI = Work Productivity and Activity Index.', 'a', 'Period 2 study drug is to be initiated upon administration of study drug dispensed at the Week 24 visit.', 'b', 'The Week 26 visit will consist of monitoring liver function tests only (ALT, AST, GGT, total and direct bilirubin, ALP); urine and additional tubes of blood', 'may be required to accommodate possible reflex testing for abnormal GGT, AST or ALT (see Table 5). If preferred by the subject and clinical site,', 'laboratory values may be drawn and resulted locally, with results entered into the CRF.', '58']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'The Investigator (or designee) must call and talk to the subject during Week 40 and 44; alternative forms of interactive communication such as returned', \"email and cellular text correspondence are acceptable. During all calls, the Investigator (or designee) will assess the subject's overall wellbeing, discuss\", 'compliance (if applicable), proper recording of attack details (if applicable), or any usability issues with the e-diary. The phone call may be omitted if the', \"subject records an attack as the Investigator must call and confirm or reject the attack (see Footnote 'm').\", 'd', 'Abbreviated physical examinations targeted to signs and symptoms will be performed at post-baseline visits.', 'e To include blood pressure and pulse rate. Prior to obtaining vital signs, subjects should rest in a supine position for at least 5 minutes.', 'f', 'Table 5 lists parameters to be assessed.', 'g', 'ECGs may be single assessments. Prior to obtaining an ECG, subjects should rest quietly in a supine position for at least 10 minutes. ECGs should be', 'obtained prior to any blood sampling. An ECG should be repeated for a change from baseline in QTcF > 60 msec or a QTcF interval > 500 msec.', 'h', 'The EQ-5D-5L will be administered once at baseline and 1 to 2 X at Weeks 28, 32, 36, and 48. The subject will fill out the first EQ-5D-5L at baseline and', 'on-study to describe their current health state today as instructed per the instrument. The subject will also fill out a second EQ-5D-5L based on a recollection', 'of their health state during an average attack that they experienced since the last study visit. If the subject has not had an attack since their last study visit, the', 'subject is not required to fill out the second, attack-related EQ-5D-5L.', 'i', 'Where possible, QoL and health outcome questionnaires should be collected as the first assessments at a visit.', 'j', 'Any issues (including mediocre or poor compliance) warranting e-diary re-education should occur on an as-needed basis.', 'k', \"At any time the e-diary is in a subject's possession up to the Week 48 visit, they will enter HAE attacks and relevant details and dosing information (as\", 'applicable) at least once per day.', '1', 'Study drug should be taken at approximately the same time each day, with whichever meal is typically the largest of the day. Subjects are not required to', 'take their doses at clinic visits.', 'm The Investigator (or designee) will review the e-diary record of all HAE attacks that occur from Screening through Week 48 and either confirm or reject the', 'attack as an HAE attack. For all attacks that occur, subjects will be contacted within approximately 2 business days of the end of the attack to discuss the', 'clinical characteristics of the attack, any questions the Investigator has on the entered data or to gain additional attack details not included in the e-diary that', 'the Investigator deems important to clinically evaluate the event, as applicable. This information, in conjunction with the e-diary record, will', 'be', 'used', 'by', 'the', 'Investigator to verify or reject the event recorded in the diary as an HAE attack. The e-diary data review, subject contact summary, and Investigator', 'verification of the attack will be documented in the source records; the Investigator attack verification (confirmed or rejected) will also be recorded.', 'n', 'Early termination visit only (if occurring during dosing phase)', 'o', 'PK and PD blood samples will be drawn on all subjects with no particular relationship to the timing of study drug dosing. The Investigator (or designee)', \"must ensure that the time of the last dose prior to PK and PD draw is recorded in the subject's e-diary (this may also be captured in the CRF).\", 'p', 'In addition to urine pregnancy tests at study visits, women of childbearing potential who enroll at sites in Europe will be dispensed urinary pregnancy tests to', 'be completed at home at Weeks 40 and 44. Sites will confirm negative test results by telephone and record in source documents.', 'q', 'Adolescent subjects will also have height measured at Week 48.', '59']\n\n###\n\n", "completion": "END"}